Next, we used touch prep-qSMLM [97] to assess plasma membrane-localized HER2 in core biopsies from six women with breast cancer prior to a neoadjuvant treatment that included chemotherapy, trastuzumab, and pertuzumab. This evidence concerns the gene ERBB2 and breast cancer.